|
1.
|
Groll M and Potts BC: Proteasome
structure, function, and lessons learned from beta-lactone
inhibitors. Curr Top Med Chem. 11:2850–2878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Voges D, Zwickl P and Baumeister W: The
26S proteasome: a molecular machine designed for controlled
proteolysis. Annu Rev Biochem. 68:1015–1068. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Maquat LE and Carmichael GG: Quality
control of mRNA function. Cell. 104:173–176. 2011. View Article : Google Scholar
|
|
4.
|
Neu-Yilik G and Kulozik AE: NMD:
multitasking between mRNA surveillance and modulation of gene
expression. Adv Genet. 62:185–243. 2008.PubMed/NCBI
|
|
5.
|
Maquat LE: Nonsense-mediated mRNA decay:
splicing, translation and mRNP dynamics. Nat RevMol Cell Biol.
5:89–99. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Czaplinski K, Ruiz-Echevaria MJ, Gonzalez
CI and Peltz SW: Should we kill the messenger? The role of the
surveillance complex in translation termination and mRNA turnover.
Bioessays. 21:685–696. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Yamashita A, Ohnishi T, Kashima I, et al:
Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein
kinase, associates with components of the mRNA surveillance complex
and is involved in the regulation of nonsense-mediated mRNA decay.
Genes Dev. 15:2215–2228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kashima I, Yamashita A, Izumi N, et al:
Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon
junction complex triggers Upf1 phosphorylation and
nonsense-mediated mRNA decay. Genes Dev. 20:355–367. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Silva AL and Romao L: The mammalian
nonsense-mediated mRNA decay pathway: to decay or not to decay!
Which players make the decision? FEBS Lett. 583:499–505. 2009.
|
|
10.
|
Lykke-Andersen J, Shu MD and Steitz JA:
Human Upf proteins target an mRNA for nonsense-mediated decay when
bound downstream of a termination codon. Cell. 103:1121–1131. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Chamieh H, Ballut L and Bonneau F: NMD
factors UPF2 and UPF3 bridge UPF1 to the exon junction complex and
stimulate its RNA helicase activity. Nat Stuct Mol Biol. 15:85–93.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Danielsen JM, Sylvestersen KB,
Bekker-Jensen S, et al: Mass spectrometric analysis of lysine
ubiquitylation reveals promiscuity at site level. Mol Cell
Proteomics. 10:M110.0035902011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ishigaki Y, Nakamura Y, Takehara T, et al:
Scanning electron microscopy with an ionic liquid reveals the loss
of mitotic protrusions of cells during the epithelial-mesenchymal
transition. Microsc Res Tech. 74:1024–1031. 2011. View Article : Google Scholar
|
|
14.
|
Xolalpa W, Perez-Galan P, Rodríguez MS, et
al: Targeting the ubiquitin proteasome system: beyond proteasome
inhibition. Curr Pharm Des. 19:4053–4093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Buac D, Shen M, Schmitt S, et al: From
Bortezomib to other inhibitors of the proteasome and beyond. Curr
Pharm Des. 19:4025–4038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kisselev AF and Goldberg AL: Proteasome
inhibitors: from research tools to drug candidates. Chem Biol.
8:739–758. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Aghajanian C, Soignet S, Dizon DS, et al:
A phase I trial of the novel proteasome inhibitor PS341 in advanced
solid tumor malignancies. Clin Cancer Res. 8:2505–2511.
2002.PubMed/NCBI
|
|
18.
|
Richardson PG, Barlogie B, Berenson J, et
al: A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Scagliotti G: Proteasome inhibitors in
lung cancer. Crit Rev Oncol Hematol. 58:177–189. 2006. View Article : Google Scholar
|
|
20.
|
Crawford LJ, Walker B and Irvine AE:
Proteasome inhibitors in cancer therapy. J Cell Commun Signal.
5:101–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lopes UG, Erhardt P, Yao R, et al:
P53-dependent induction of apoptosis by proteasome inhibitors. J
Biol Chem. 272:12893–12896. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Pleban E, Bury M, Mlynarczuk I, et al:
Effects of proteasome inhibitor PSI on neoplastic and
non-transformed cell lines. Folia Histochem Cytobiol. 39:133–134.
2001.PubMed/NCBI
|
|
23.
|
Nakanishi C and Toi M: Nuclear
factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Mitsiades N, Mitsiades CS, Poulaki V, et
al: Molecular sequelae of proteasome inhibition in human multiple
myeloma cell. Proc Natl Acad Sci USA. 99:14374–14379. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Russo A, Bronte G, Fulfaro F, et al:
Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr
Cancer Drug Targets. 10:55–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Garneau NL, Wilusz J and Wilusz CJ: The
highways and byways of mRNA decay. Nat Rev Mol Cell Biol.
8:113–126. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Takahashi S, Araki Y, Ohya Y, et al: Upf1
potentially serves as a RING-related E3 ubiquitin ligase via its
association with Upf3 in yeast. RNA. 14:1950–1958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kuroha K, Tatematsu T and Inada T: Upf1
stimulates degradation of the product derived from aberrant
messenger RNA containing a specific nonsense mutation by the
proteasome. EMBO Rep. 10:1265–1271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Melero R, Buchwald G, Castaño R, et al:
The cryo-EM structure of the UPF-EJC complex shows UPF1 poised
toward the RNA 3′ end. Nat Struct Mol Biol. 19:498–505.
2012.PubMed/NCBI
|
|
30.
|
Silver DL, Watkins-Chow DE, Schreck KC, et
al: The exon junction complex component Magoh controls brain size
by regulating neural stem cell division. Nat Neurosci. 13:551–558.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Silver DL, Leeds KE, Hwang HW, et al: The
EJC component Magoh regulates proliferation and expansion of neural
crest-derived melanocytes. Dev Biol. 375:172–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Albers CA, Paul DS, Schulze H, et al:
Compound inheritance of a low-frequency regulatory SNP and a rare
null mutation in exon-junction complex subunit RBM8A causes TAR
syndrome. Nat Genet. 44:435–439. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Alachkar A, Jiang D, Harrison M, et al: An
EJC factor RBM8a regulates anxiety behaviors. Curr Mol Med.
13:887–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Weischenfeldt J, Damgaard I, Bryder D, et
al: NMD is essential for hematopoietic stem and progenitor cells
and for eliminating by-products of programmed DNA rearrangements.
Genes Dev. 22:1381–1396. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Long AA, Mahapatra CT, Woodruff EA III, et
al: The nonsense-mediated decay pathway maintains synapse
architecture and synaptic vesicle cycle efficacy. J Cell Sci.
123:3303–3315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Thoren LA, Nørgaard GA, Weischenfeldt J,
et al: UPF2 is a critical regulator of liver development, function
and regeneration. PLoS One. 5:e116502010. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Nguyen LS, Kim HG, Rosenfeld JA, et al:
Contribution of copy number variants involving nonsense-mediated
mRNA decay pathway genes to neuro-developmental disorders. Hum Mol
Genet. 22:1816–1825. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Jolly LA, Homan C, Jacob R, et al: The
UPF3B Gene, implicated in intellectual disability, autism, ADHD and
childhood onset Schizophrenia regulates neural progenitor cell
behaviour and neuronal outgrowth. Hum Mol Genet. July 10–2013.(Epub
ahead of print).
|
|
39.
|
Nguyen LS, Jolly L, Shoubridge C, et al:
Transcriptome profiling of UPF3B/NMD-deficient lymphoblastoid cells
from patients with various forms of intellectual disability. Mol
Psychiatry. 17:1103–1115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Szyszka P, Sharp SI, Dedman A, et al: A
nonconservative amino acid change in the UPF3B gene in a patient
with schizophrenia. Psychiatr Genet. 22:150–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Addington AM, Gauthier J, Piton A, et al:
A novel frame-shift mutation in UPF3B identified in brothers
affected with childhood onset schizophrenia and autism spectrum
disorders. Mol Psychiatry. 16:238–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
